- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | FluoGuide A/S Publishes Interim Report H1 2025 | 133 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 28, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 28 August 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period... ► Artikel lesen | |
| 22.08. | Invitation to FluoGuide A/S Webcast on 28 August 2025 | 216 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 22, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025.The following event will take place later... ► Artikel lesen | |
| 21.07. | FluoGuide A/S: FluoGuide Enters Collaboration with Global MedTech Company Olympus | 353 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 21, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 03.07. | FluoGuide A/S: Update on 2025 Outlook and Company progress | 151 | GlobeNewswire (Europe) | Copenhagen, Denmark, 3 July 2025 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2025 Outlook... ► Artikel lesen | |
| 10.06. | FluoGuide A/S: FG001 clinical data in High-Grade Glioma is now published in Neurosurgery | 534 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision... ► Artikel lesen | |
| 28.05. | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - March 2025 - On track - first patients enrolled in CT-005 | 193 | GlobeNewswire (Europe) | Copenhagen, Denmark, 28 May 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2025. The Q1 report is available as an attached document... ► Artikel lesen | |
| 15.04. | FluoGuide A/S: FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer | 173 | GlobeNewswire (Europe) | Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase... ► Artikel lesen | |
| 27.03. | Minutes from Annual General Meeting in FluoGuide A/S | 289 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 12.03. | Notice of Annual General Meeting in FluoGuide A/S | 350 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64... ► Artikel lesen | |
| 27.02. | FluoGuide A/S Publishes Interim Report for the Period January - December 2024 | 269 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / February 27, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for... ► Artikel lesen | |
| 27.02. | FluoGuide A/S Publishes Year-End and Annual Report for the Fiscal Year 2024 | 345 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / February 27, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - FluoGuide A/S ("FluoGuide" or the "Company") hereby publishes its annual report... ► Artikel lesen | |
| 15.01. | FluoGuide A/S Receives Approval for Phase II Trial in Head and Neck Cancer | 336 | ACCESS Newswire | KØBENHAVN, DK / ACCESSWIRE / January 15, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery... ► Artikel lesen | |
| 27.11.24 | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - September 2024 | 270 | GlobeNewswire (Europe) | Copenhagen, Denmark, 27 November 2024 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January 2024 - 30 September 2024. The Q3 report is available as attached... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 42,170 | +0,43 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,100 | -0,30 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS | 46,880 | +0,13 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Fresenius von 49 auf 57 Euro angehoben und die Einstufung auf "Buy" belassen. Die Phase steigender Markterwartungen sei bei... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,960 | -0,97 % | INDEX-MONITOR: JPMorgan erwartet Fraport, Nordex und Flatexdegiro im Stoxx 600 | FRANKFURT (dpa-AFX) - Fünf Aufsteiger erwartet die US-Bank JPMorgan im September im Stoxx Europe 600 . Darunter sollten drei deutsche Unternehmen sein, während zugleich aber auch zwei oder gar drei... ► Artikel lesen | |
| RXSIGHT | 8,890 | 0,00 % | RxSight: Strategische Neuausrichtung angesichts von Marktherausforderungen | ||
| UNITEDHEALTH | 273,50 | +1,62 % | Gesundheitssektor jetzt unterbewertet? PanGenomic Health, Redcare Pharmacy, UnitedHealth Group | Der Zoll-Streit der USA mit dem Rest der Welt geht in die nächste Runde. Wie ein US-Berufsgericht im demokratisch geführten Bundesstaat Kalifornien verkündete, ist der US-Präsident Donald Trump nicht... ► Artikel lesen | |
| GERRESHEIMER | 41,220 | -0,05 % | Gerresheimer Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| GENEDX | 132,49 | 0,00 % | GeneDx stellt auf Wells Fargo Konferenz strategische Vision für Diagnostik vor | ||
| GOODRX | 3,995 | 0,00 % | Mizuho belässt GoodRx-Aktie trotz Novo-Nordisk-Partnerschaft auf "Neutral" | ||
| LIFEMD | 6,060 | 0,00 % | Pre-market Movers: Myriad Genetics, LifeMD, Evolus, Lantheus Holdings, Astera Labs | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04.
Astera... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 15,845 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Earns Spot on Newsweek's World's Most Trustworthy Companies 2025 List for Third Consecutive Year | ||
| HIMS & HERS HEALTH | 41,620 | +0,73 % | Hims & Hers Health schließt 15-jährigen Mietvertrag in Ohio über 5,98 Millionen US-Dollar Jahresmiete ab | ||
| CERIBELL | 11,800 | 0,00 % | Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware | SUNNYVALE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a leading medical technology company transforming the diagnosis and management of patients with serious... ► Artikel lesen | |
| OPTIMIZERX | 18,820 | 0,00 % | OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth | WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 40,640 | 0,00 % | Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts |
FLUOGUIDE A/S gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 3,360 Euro und damit -1,75 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.